TD-HS870116

Camrelizumab(TD-HS870116) is a research-grade recombinant antibody targetingCD1. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.

Human

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Humanized

IgG4-kappa

Monoclonal

Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279

Please contact the lab for this information.

>95% purity as determined by SDS-PAGE.

Protein A/G purified from cell culture supernatant.

Q15116

Liquid

0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

SHR-1210, 1798286-48-2

Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. PD-1 is a negative regulator of immune activation that is considered a foundational target within the immuno-oncology market.• The blockade of immune checkpoints in cancer immunotherapy., PMID:22437870• PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations., PMID:30888929• The diverse functions of the PD1 inhibitory pathway., PMID:28990585• PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy., PMID:30191996• Immune Checkpoint Blockade in Cancer Therapy., PMID:25605845• PD-1 expression and clinical PD-1 blockade in B-cell lymphomas., PMID:29118007• Overcoming T cell exhaustion in infection and cancer., PMID:25797516• Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker., PMID:32875727• Tumor Mutational Burden and Response Rate to PD-1 Inhibition., PMID:29262275• PD-L1., PMID:29097600

Detects Human CD279/PDCD1/PD1 in indirect ELISAs.　　|　SDS-PAGE for Research Grade Camrelizumab.

For research use only. Not suitable for clinical or therapeutic use.